| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) is a naturally occurring naphthoquinone derivative. –Plumbagin can undergo redox cycling to generate reactive oxygen species (ROS) -apototosis, activation of caspases, modulation of Bax, Bcl‑2, loss of MMP. -Cell cycle arrest in cancer cells, often at the G0/G1, or G2/M phases. -May inhibit NF‑κB activation – MAPK Pathways – PI3K/Akt Pathway -Downregulation of (VEGF) and matrix metalloproteinases (MMPs). -Seems capable of raising ROS in normal and cancer cells (#2004) -ic50 cancer cells 1-10uM, normal cells >10uM
|
| Source: |
| Type: protein |
| DR4 (Death Receptor 4, also known as TRAIL receptor 1 or TNFRSF10A). DR4 is one of the main receptors for TRAIL (TNF-related apoptosis-inducing ligand). • Upon TRAIL binding, DR4 can trigger the extrinsic apoptotic pathway, leading to caspase activation and programmed cell death. Lower receptor levels often correlate with therapy resistance and aggressive tumor phenotypes, while appropriate or higher levels may enhance susceptibility to apoptosis-based therapies. |
| 5159- | PLB, | Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression |
| - | in-vitro, | AML, | K562 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:299 Target#:806 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid